Off the coast of Central America, the Sea Diva, a tuna boat, sinks. Members of the crew are missing and what happened remains a mystery. As the case goes to trial, a missing crew member is believed to be at fault, but new evidence comes to light and the finger of guilt points in a completely unanticipated direction. Learn more here: http://bit.ly/1LHfMJ0
A recently published scientific study from Lund University by lead researcher Charlotte Erlanson-Albertsson, MD, PhD found that subjects who were trying to lose weight and used the patented spinach extract Appethyl on a daily basis lost 43 percent more weight compared to those ingesting a placebo.
In this clinical trial, overweight women were given either a daily five gram dose of Appethyl or a control drink immediately before breakfast. Researchers found that the weight of the women ingesting Appethyl decreased significantly at 43 percent more than subjects ingesting the control drink.
This is one of three studies that also compared the effects of Appethyl after 90 days with those found after the first dose and found no decline of effects, indicating that Appethyl takes effect after the first dose and is just as effective after long-term use. One study showed that Appethyl reduced hunger by 25 percent four hours after consumption, in addition to reducing thoughts about food by 33 percent.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7426951-appethyl-spinach-extract/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
The Great Depression was a time of sacrifice, and sixteen-year-old Sooze Williams chooses to sacrifice her heart and her future to help her family and save her brother. A murder, a betrayal, a trial. If you like Steinbeck and Grisham you will want to read Shadow of the Hawk by K.S. Jones. Find out more at http://ksjones.com. #ShadowoftheHawk Thriller/Literary/YA
Turn Your Dull Pictures Taken from Mobile into Vibrant Pics That Speak a Million Words. Learn For Free, Few Chapters Are Being Taught by a 9 year Old 5th Grade Girl, Which Has Become the Talking Point of Media Worldwide. Watch the Preview Promo to know different ways of how you can make your pictures stunning enough to post on the Social Media. A 9 year old 5th grade girl teaches you few amazing tricks that can transform your pictures instantly. Before experimenting any new look at beauty salon, you can first try it on your photograph. Now pimples & acne can't hide the actual beauty of yours, learn how to make your pimples & acne do the vanishing act on your photograph With RK Photo magic trix. Use Trial & Error methods to find out which colors of your Lipstick, Eye Shadow, Tattoo, Blush On, Mehndi, Dress Color & Hairstyle looks best on you, also learn to do extreme make up on your photographs. Listen to the peppy African Theme song recorded in Africa & Sung by an African. A fifth standard girl Arkshya Raj Kalra along with her father is teaching some interesting & simple tricks of Photoshop & in the process the International Media has already started talking & writing about this simplified tutorials aimed at rectifying the problems that everyone faces in their pictures. For more updates and Photo Trix ... like RKPhotoMagicTrix Facebook page --
https://www.facebook.com/rkphotomagictrix
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
The Alfred Mann Foundation (AMF) today announced the first subject, a U.S. Marine, SSgt James Sides, as a recipient of its highly anticipated IMES System (implantable myoelectric sensor) – an experimental system that holds the promise of being the first minimally invasive, intuitive, multi-channel control system for prosthetics intended for long term use. The IMES System is currently being studied under the Investigational Device Exemption (IDE) regulations of the U.S. Food and Drug Administration (FDA). AMF’s ongoing trial with injured veterans at the Walter Reed National Medical Military Center anticipates subjects intuitively operating three different prosthetic movements simultaneously: opening and closing the hand, rotating the wrist, and moving the thumb. Combining these three movements enables several grasps that are invaluable for performing everyday tasks.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65112-alfred-mann-foundation-u-s-marine-subject-fda-study-for-imes-system
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg® compared to biphasic insulin aspart 30, both administered twice-daily1.
Ryzodeg® is the first combination of two distinct insulin analogues, Tresiba® (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid® (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes2-4.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control
Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
New research has revealed that the use of Antimicrobial Copper surfaces in hospital rooms can reduce the number of healthcare-acquired infections (HAIs) by 58% as compared to patients treated in Intensive Care Units with non-copper touch surfaces. In the United States, 1 out of every 20 hospital patients develops an HAI, resulting in an estimated 100,000 deaths per year. Although numerous strategies have been developed to decrease these infections, Antimicrobial Copper is the only strategy that works continuously, has been scientifically proven to be effective and doesn’t depend on human behavior, according to a recently published study in the SHEA Journal of Infection Control and Hospital Epidemiology.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61120-antimicrobial-copper-surfaces-reduce-healthcare-acquired-infections
http://www.greatsouthernoutdoors.com/book_a_hunt/quail_hunting/ Sweet Home Alabama Quail Hunting Great Southern Outdoors prides itself being located in the region known as the Field Trial Capital of the World. Quail hunting in this area has been a gentlman's sport since the 1800′s when plantation owners would get involved in friendly competition. Now it has become a well liked sport by both outdoors-men and women. Great Southern Outdoors quail staff, Josh, Mark, Freeman, and Hunter enjoy the sport as much as our hunters and a little friendly competition only makes it more exciting.You are sure to have an experience of a lifetime just watching the dogs work and being in the Great Southern Outdoors.
